

# MDR Conformity Assessment Routes



## Contents

- 2 Class Is/Im/Ir devices
- 3 Class IIa devices
- 5 Class IIb Annex VIII Rule 12 devices
- 6 Class IIb implantable WET Class IIb non-implantable non Rule 12 non WET
- 8 Class IIb implantable devices (Excluding WET)
- 9 Class III non-implantable devices
- 10 Class III implantable devices
  - DISCLAIMER:


Information presented in the conformity assessment flow charts and tables below is based on our current understanding of the MDR requirements at the time of publishing this document; subject to change. The tables do not cover assessments under the conformity routes Annex X (Type Examination) and Annex XI, Part B (Product Verification) which may require additional tests or examinations of the devices. The tables present a generalization of the requirements based on the classification of devices and some exceptions may apply.

- 11 Custom-made Class III implantable devices
- 12 Custom-made devices (Excluding custom-made Class III implantable edvices)

**Class I devices** (Excluding Class Is, Ir, Im devices)

13 How BSI supports your Medical Devices launch CE Excellence

## Class Is/Im/Ir devices



## Applicable audits, assessments and requirements

Class Is/Im/Ir devices

Class Is/Im/Ir	Initial	Surveillance					
devices	Conformity Assessment	Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes	
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A	
Technical Documentation Assessment	No stand-alone Te of Technical Docur aspects may b	nentation r	elevant to s	sterilization	/metrology	/re-use	
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A	
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A	
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A	

**Clinical Evaluation Report updates** 

Post Market Clinical Follow-Up Update Report (Article 61)

Post Market Surveillance (PMS) Report (Article 80)

Periodic Safety Update Report (Article 86)

**Unannounced Audits** 

\* If sterile or re-usable surgical instruments.

\*\* The Y3 "Recert" indicated in the table refers to the recertification audit related to EN ISO 13485:2016 certificate cycle which is typically three years. Most manufacturers with MDR/IVDR certificates also hold EN ISO 13485 certificate.


Updated as per manufacturer's clinical evaluation plan.
Undated as nor manufacturor's DMS_DMCE plans

Updated as per manufacturer's PMS, PMCF plans. Notified Body QMS audits to verify implementation of the plan by sampling complaints, vigilance information etc.

Updated when necessary and made available to the Notified Body upon request.

N/A	N/A	N/A	N/A	N/A
At least o	nce every 5	5 years.		

## **Class IIa devices**



## Applicable audits, assessments and requirements

Class IIa non-implantable devices

Class IIa	Initial	Surveillance						
non-implantable devices	Conformity Assessment	Y1	Y2	Y3	Y4	Y5		
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes		
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A		
Technical Documentation Assessment	Sample per category of devices	assessr	nent is req out as per	cal Docume uired every the Technic ampling Pla	year. Asses al Docume	sments		
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A		
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A		
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A		

**Clinical Evaluation Report updates** 

Post Market Clinical Follow-Up Update Report (Article 61)

Periodic Safety Update Report (Article 86)

### **Unannounced Audits**

\* If sterile or re-usable surgical instruments.

\*\* The Y3 "Recert" indicated in the table refers to the recertification audit related to EN ISO 13485:2016 certificate cycle which is typically three years. Most manufacturers with MDR/IVDR certificates also hold EN ISO 13485 certificate.

Updated as per manufacturer's clinical evaluation plan. Notified Body to review as per Technical Documentation Sampling Plan.

Updated as per manufacturer's PMS, PMCF plans. Notified Body to review as per Technical Documentation Sampling Plan.

PSUR update required at least once every 2 years. Notified Body to review as per Technical Documentation Sampling Plan.

At least once every 5 years.

Continues on page 4


## **Applicable audits, assessments and requirements** Class IIa implantable devices

Class IIa	Initial	Surveillance						
implantable devices	Conformity Assessment	Y1	Y2	Y3	Y4	Y5		
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes		
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A		
Technical Documentation Assessment	Sample per category of devices	assess	ment is rec d out as pe	ical Docume quired every r the Techni ampling Pla	year. Asses	ssments		
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A		
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A		
Summary of Safety and Clinical Performance (Article 32)	Yes	Body to r	eview as p	nually "if inc er Technica : the time of	l Documen	itation		

Clinical Evaluation Report updates	Updated as per manufacturer's clinical evaluation plan. Notified Body to review updates as per Technical Documentation Sampling Plan or at the time of PSUR assessments.
Post Market Clinical Follow-Up Update Report (Article 61)	Updated at least annually. Notified Body to review as per Technical Documentation Sampling Plan or at the time of PSUR assessments.
Periodic Safety Update Report (Article 86)	Updated when necessary and at least every two years. submitted to Notified Body via EUDAMED for Notified Body review.
Unannounced Audits	At least once every 5 years.

\* If sterile or re-usable surgical instruments.

## **Class IIb Annex VIII Rule 12 devices**



## Applicable audits, assessments and requirements


Class IIb Annex VIII Rule 12 devices

Annex VIII Rule 12 devices - All active devices intended to administer and/or remove medicinal products, body liquids or other substances to or from the body.

Class IIb	Initial	Surveillance					
Annex VIII Rule 12 devices	Conformity Assessment	Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes	
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A	
Technical Documentation Assessment	Sample per generic device group	At least one Technical Documentation surveill assessment is required every year. Assessme carried out as per the Technical Documentat Sampling Plan.					
Clinical Evaluation Consultation Procedure (Article 54)	Yes, but exemptions may apply as per Article 54.2	May be required if any modifications to the de adversely affect the risk-benefit ratio.					
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A	
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A	
Clinical Evaluation Report update	s	plan. Not	ified Body	nufacturer's to review up tation Samp	odates as p		
Post Market Clinical Follow-Up Up (Article 61)	odate Report	Updated as per manufacturer's PMCF plan Notified Body to review updates as per Technical Documentation Sampling Plan.					
Periodic Safety Update Report (Article 86)				nually. Notifi nical Docum			
Unannounced Audits		At least o	nce every	5 years.			

\* If sterile or re-usable surgical instruments.

## Class IIb implantable WET Class IIb non-implantable non Rule 12 non WET



### Applicable audits, assessments and requirements Class IIb implantable WET, ClassIIb non-implantable non Rule 12 non WET

Well-Established Technologies (WET) - sutures, staples, dental fillings and braces, tooth crowns, screws, wedges, plates, wires, pins, clips & connectors as per Article 52 of MDR.

Class IIb	Initial Conformity Assessment	Surveillance					
implantable WET devices		Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes	
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A	
Technical Documentation Assessment	Sample per generic device group	At least one Technical Documentation surveilla assessment is required every year. Assessme carried out as per the Technical Documentati Sampling Plan.					
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A	
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A	
Summary of Safety and Clinical Performance (Article 32)	Yes	Body to re Documer	eview upda	nually "if ind ates as per ppling Plan ts.	Technical		
Clinical Evaluation Report updates	5	plan. Not	ified Body	nufacturer's to review a npling Plan	s per Techr		
Post Market Clinical Follow-Up Up (Article 61)	date Report	Updated at least annually. Notified Body to review updates as per Technical Documentation Samplin Plan or at the time of PSUR assessments.					
Periodic Safety Update Report (Article 86)		Body via l	EUDAMED	nually. Subm for Notified ces are impl	Body revie	W	
Unannounced Audits		At least o					

\* If sterile or re-usable surgical instruments.

\*\* The Y3 "Recert" indicated in the table refers to the recertification audit related to EN ISO 13485:2016 certificate cycle which is typically three years. Most manufacturers with MDR/IVDR certificates also hold EN ISO 13485 certificate.

Continues on page 7

# **Applicable audits, assessments and requirements** Class IIb non-implantable non WET non Rule 12 devices

Class IIb	Initial	Surveillance					
non-implantable non-WET non-Rule 12 devices	Conformity Assessment	Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes	
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A	
Technical Documentation Assessment	Sample per generic device group	At least one Technical Documentation surveill assessment is required every year. Assessme carried out as per the Technical Documentat Sampling Plan.					
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A	
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A	
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A	
Clinical Evaluation Report update	s	Updated as per manufacturer's clinical evaluation plan. Notified Body to review as per Technical Documentation Sampling Plan.					
Post Market Clinical Follow-Up Up (Article 61)	odate Report	Notified E	Body to rev	nufacturer's iew updates ipling Plan.			
Periodic Safety Update Report (Article 86)		Updated at least annually. Notified Body to review updates as per Technical Documentation Sampling Plan.					


**Unannounced Audits** 

\* If sterile or re-usable surgical instruments.

\*\* The Y3 "Recert" indicated in the table refers to the recertification audit related to EN ISO 13485:2016 certificate cycle which is typically three years. Most manufacturers with MDR/IVDR certificates also hold EN ISO 13485 certificate.

At least once every 5 years.

# Class IIb implantable devices Excluding WET




## Applicable audits, assessments and requirements

Class IIb implantable non-WET devices

Class IIb	Initial Conformity Assessment	Surveillance					
implantable non-WET devices		Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes	
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A	
Technical Documentation Assessment	Review for every device	N/A	N/A	N/A	N/A	N/A	
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A	
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A	
Summary of Safety and Clinical Performance (Article 32)	Yes	Body to re		nually "if ind e time of PS ews.			
Clinical Evaluation Report updates		plan. Not	ified Body	nufacturer's to review at ial change r	the time o		
Post Market Clinical Follow-Up Ur (Article 61)	odate Report	Updated at least annually. Notified Body to review at the time of PSUR reviews or substantial change reviews.					
Periodic Safety Update Report (Article 86)				nually. Subm for Notified			

## Class III non-implantable devices



## Applicable audits, assessments and requirements


Class III non-implantable devices

Including devices with medicinal substances, human tissue or animal tissue derivatives with TSE risk, Class III Rule 21 devices.

Class III	Initial	Surveillance					
non-implantable devices	Conformity Assessment	Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes	
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A	
Technical Documentation Assessment	Review for every device	N/A	N/A	N/A	N/A	N/A	
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A	
Consultations (Rule 14, Rule 18, Rule 21)	If applicable	suppleme	entary cons asis taking	devices ma ultations; d into accour	etermined		
Summary of Safety and Clinical Performance (Article 32)	Yes	Body to re		nually "if ind e time of PS reviews			
Clinical Evaluation Report updates	5	plan. Not	ified Body 1	nufacturer's to review at ial change	the time c		
Post Market Clinical Follow-Up Up (Article 61)	date Report			nually. Noti reviews or s			
Periodic Safety Update Report (Article 86)				nually. Subm for Notified			
Unannounced Audits		At least o	nce every	5 years.			

\* If sterile or re-usable surgical instruments.

## Class III implantable devices




## Applicable audits, assessments and requirements Class III implantable devices

Including devices with medicinal substances, human tissue or animal tissue derivatives with TSE risk, Class III Rule 21 devices.

Class III	Initial	Surveillance					
implantable devices	Conformity Assessment	Y1	Y2	Y3	Y4	Y	
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Ye	
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/	
Technical Documentation Assessment	Review for every device	N/A	N/A	N/A	N/A	N/	
Clinical Evaluation Consultation Procedure (Article 54)	Yes, but exemptions may apply as per Article 54.2						
Consultations (Rule 14, Rule 18, Rule 21)	If applicable	suppleme case-by-c	entary con	e devices m sultations; c aking into a posed.	determine		
Summary of Safety and Clinical Performance (Article 32)	Yes	Body to re		nually 'if indi le time of PS reviews.			
Clinical Evaluation Report updat	tes	plan. Not	ified Body	nufacturer's to review at ial change i	the time		
Post Market Clinical Follow-Up L (Article 61)	Jpdate Report	Updated	at least ar	nually. Noti views or su			
	Jpdate Report	Updated the time reviews. Updated a	at least ar of PSUR re at least ani	nually. Noti	bstantial o	tified	

## Custom-made Class III implantable devices



### Applicable audits, assessments and requirements Custom-made Class III implantable devices


Custom-made Class III implantable devices	Initial Conformity Assessment	Surveillance					
		Y1	Y2	Y3	Y4	Y5	
QMS Audits	Yes	Yes	Yes	Recert**	Yes	Yes	
Microbiology Audits	Yes*	N/A	N/A	Yes*	N/A	N/A	
Technical Documentation Assessment	No stand-alone Technical Documentation assessment. However, relevant parts of Technical Documentation may be audited as part of QMS/ Microbiology audits.						
Clinical Evaluation Consultation Procedure (Article 54)	N/A	N/A	N/A	N/A	N/A	N/A	
Consultations (Rule 14, Rule 18, Rule 21)	N/A	N/A	N/A	N/A	N/A	N/A	
Summary of Safety and Clinical Performance (Article 32)	N/A	N/A	N/A	N/A	N/A	N/A	
Clinical Evaluation Report updates		N/A	N/A	N/A	N/A	N/A	
Post Market Clinical Follow-Up Update Report (Article 61)		As per manufacturer's PMS, PMCF plans. Notified Body QMS audits to verify implementation of the plan.					
Periodic Safety Update Report (Article 86)		Updated at least annually. Not required to be submitted to EUDAMED for Notified Body review. Notified Body to verify updates at the time of surveillance QMS audits.					
Unannounced Audits			At least once every 5 years.				

\* If sterile or re-usable surgical instruments.

## Custom-made devices

Excluding custom-made Class III implantable devices

## **Class I devices** Excluding Class Is, Ir, Im devices



implantable devices



## How BSI supports your Medical Device launch

## **CE Excellence**

### Readiness

In the competitive medical device marketplace, ensuring that product development meets all regulatory requirements is essential. We support you through the application and certification process.

### **Worldwide Access**

We offer a wide range of regulatory and quality management programs that work cohesively for international compliance. Our Quality Management System (QMS) solutions include ISO 13485, ISO 9001, ISO 14001 and many more.

We are a recognized certification body in Japan, Malaysia, Singapore and Taiwan, and a recognized MDSAP auditing organization for all participating regulatory authorities.


### **BSI Transfer**

We offer a seamless transfer to our services providing comprehensive support to ensure minimal disruption to your company.

### **Additional Services**

- Access to more than 34,000 standards and related products, as well as online guidance documents.
- **Expert training** online or face-to-face through our public training courses.
- **Regulatory updates and newsletters** focusing on industry changes, helping you to plan for the future.
- Webinars delivered by our experts on regulatory issues.
- **Comprehensive white papers** providing the latest insights on key industry topics.

BSI CE-Exellence Programs are designed to support manufacturers seeking timely and effective market access. Our services combine efficiency with the integrity, independence, and thoroughness you expect from BSI.



### **CE-Standard**

The Standard review service allows you to work closely with your assigned BSI Product Expert on your product certification. These reviews are conducted remotely, with communication between you and your BSI Product Expert via phone and email as required.

### **CE-Dedicated**

The Dedicated review service allows a technical document review to be booked in advance. It is conducted remotely with your BSI Product Expert, who uses your allocated time, to conduct a focused review of your technical documentation. This allows you to interact with your BSI Product Expert, and provide information during the review. By improving the efficiency of the process, this service provides predictability in your review planning.



### Get in touch

Whether you are starting the certification process, looking to transfer or need to discuss your options, we can guide you through the process.

Request a quote

For more information on our Excellence services

Call BSI on +44 345 080 9000, visit our **CE marking webpage** and read our **Excellence Pathways brochure** 

**Note:** Our services do not guarantee an EU/UKCA certificate will be issued or that it will be issued within a certain number of working days but they are based on completeing the review process with either a positive or negative recommendation. CE and UKCA Dedicated Review service is not available for devices utilizing animal issue derivatives or medicinal substances.



# Your partner in progress

### BSI Assurance UK Ltd (0086)

Kitemark Court, Davy Avenue, Knowlhill, Milton Keynes, MK5 8PP United Kingdom

+44 345 080 9000



Find our services at bsigroup.com/medical

### BSI Group The Netherlands B.V. (2797)

Say Building, John M. Keynesplein 9 1066 EP Amsterdam The Netherlands

+31 20 346 0780



Email us at medicaldevices@bsigroup.com

### **BSI Group America Inc.**

12950 Worldgate Drive, Suite 800 Herndon, VA 20170 USA

+1 800 862 4977



Find us on LinkedIn

